This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
by Zacks Equity Research
VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
by Zacks Equity Research
Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.
DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull
by Zacks Equity Research
Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology (ALGN) consistently invests in R&D for product innovation.
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.
Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View
by Zacks Equity Research
Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.
Wright Medical (WMGI) Portfolio Solid, Lower Extremities Dull
by Zacks Equity Research
Wright Medical (WMGI) is focusing on product innovation through research and development. However, lackluster international performance of the Lower extremities segment is a matter of concern.
QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View
by Zacks Equity Research
QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
by Zacks Equity Research
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.
CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View
by Zacks Equity Research
CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.
Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline
by Zacks Equity Research
Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.
Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.
CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down
by Zacks Equity Research
CONMED (CNMD) gains from strength in General Surgery business in Q3, driven by strong performances by Advanced Surgical and Endoscopic Technologies.
Cardinal Health (CAH) Beats on Q1 Earnings, FY18 View Intact
by Zacks Equity Research
Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.
6 Solid Dividend Growth Stocks for Higher Returns
by Sweta Killa
Given that the stock market is at its peak, investors are looking for both income and growth in their portfolios.
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioSrip (BIOS) Q3 revenues affected by the company's shift in strategy to focus on core revenue mix, the impact of the Cures Act and contract modifications with UnitedHealthcare.
Bruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) raises 2017 guidance. The year-over-year increase in Q3 revenues encourages.
Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
by Zacks Equity Research
PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
by Zacks Equity Research
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
Align Technology (ALGN) Gains on InvisAlign, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.